A Pioneer in Innovative Drugs Goes Bankrupt: Investors Lost Big

▤ Summary

This article examines the bankruptcy of Sangamo Therapeutics, a long-time pioneer in gene editing. The company’s ZFN platform lost ground to CRISPR, and its commercial path never matured into a scalable approved therapy business. Sangamo has now entered bankruptcy proceedings, opened an asset sale, and begun layoffs while buyers line up for selected programs and platforms. The piece also uses Sangamo’s collapse to highlight wider pressure across the biotech sector, where high costs, long development cycles, and weak commercialization are forcing a wave of restructuring.

▦ Linked Companies